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Ampliﬁcation of Aurora-A, encoding a cell cycle-regulating kinase, has been reported in human can-
cers. Although Aurora-A is known to directly phosphorylate and down-regulate p53, the detailed
mechanism remains unclear. Here we show that Aurora-A phosphorylates hnRNPK, a transcriptional
coactivator of p53, on serine 379. This phosphorylation does not affect the post-transcriptional activ-
ity or cellular localization of hnRNPK, but disrupts its interaction with p53. Inverse correlation
between Aurora-A activity and hnRNPK-p53 interaction was further demonstrated in DNA-damaged
cells. Our results provide an alternative mechanism, whereby via phosphorylating hnRNPK Aurora-A
participates in regulating p53 activity during DNA damage.
Structured summary of protein interactions:
Aurora-A physically interacts with hnRNPK by anti tag coimmunoprecipitation (View interaction)
p53 physically interacts with hnRNPK by pull down (View interaction)
p53 physically interacts with hnRNPK by anti bait coimmunoprecipitation (View interaction)
hnRNPK physically interacts with p53 by anti bait coimmunoprecipitation (View interaction)
Aurora-A phosphorylates hnRNPK by protein kinase assay (View interaction)
hnRNPK physically interacts with Aurora-A by anti bait coimmunoprecipitation (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Aurora-A is a cell cycle-regulating serine/threonine kinase
whose expression and activity are elevated during mitosis and de-
creased after metaphase [1,2]. Aurora-A gene is located on the hu-
man chromosome locus 20q13 where commonly undergoes
ampliﬁcation in human cancers including breast, gastric, pancre-
atic, bladder, ovarian, esophageal, and colorectal cancers [3–9].
Moreover, ectopic expression of Aurora-A in NIH3T3 and Rat1 cells
have been demonstrated to induce cell transformation [3,10].
Previous studies showed that Aurora-A-induced phosphoryla-
tions of p53 repress the transcriptional activity and induce its deg-
radation [11,12]. Interestingly, a transcriptional coactivator of p53
during DNA damage, the heterogeneous nuclear ribonucleoprotein
K (hnRNPK), was also proposed as a putative substrate of Aurora-A
in vitro [13]. When cells are treated with UV or ionizing radiation,
p53 strongly interacts with hnRNPK and induces the transcription
of p53 target genes. Furthermore, such DNA damage-induced
transcriptional activity of p53 is abrogated by hnRNPK depletionchemical Societies. Published by E[14]. However, it remains uncertain whether Aurora-A directly
phosphorylates hnRNPK and accordingly regulates p53.
HnRNPK is a poly(C)-binding protein that participate in chroma-
tin remodeling, transcription, RNA splicing, mRNA stability and
translation [15]. It is predominantly localized in nucleus but also
present in cytoplasm and mitochondria [16,17]. HnRNPK is com-
posed of three K homology (KH) domains responsible for DNA/RNA
binding and one K-interactive (KI) region for protein-protein inter-
actions (Fig. 1). Several post-translational modiﬁcations of hnRNPK
have been shown to regulate its DNA-binding, translational regula-
tion, localization, and protein-protein interaction [18–24]. In this
study, we demonstrated that Aurora-A directly interacts with and
phosphorylates hnRNPK on Ser-379 in vitro and in vivo. In addition,
such phosphorylation disrupts the association of hnRNPKwith p53.
2. Materials and methods
2.1. Plasmids
Recombinant p53, Aurora-A or hnRNPK were constructed in
pGEX4T2, pET29a or pET23a vectors respectively. Mammalian
cell-expressed p53 and Aurora-A were constructed in pCMV2-Flag
vector, and hnRNPK was constructed in pCI-neo vector. All mutantlsevier B.V. All rights reserved.
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Fig. 1. Representative domain structure of hnRNPK. NLS, nuclear localization signal. KH, K homology domain. KI, K interactive region. KNS, nuclear shuttling domain.
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(Stratagene).
2.2. Cell culture, transfection and synchronization
HEK293 and 293T cells were cultured at 37 C and 5% CO2 atmo-
sphere in Dulbecco’s modiﬁed Eagle’s medium (Biochrom KG,
Berlin, Germany) supplemented with 10% fetal bovine serum
(HyClone, Logan, UT), L-glutamine, penicillin, and streptomycin.
Transient transfection was performed using TurboFect™ (Fermen-
tas) according to the manufacturer’s instruction. HEK293 cells
were synchronized in G2/M-phase by exposure to 100 ng/ml noco-
dazole for 16 h, followed by treatment with 10 lM VX-680 or
25 lM etoposide for 2 h. The cells were allowed to recover from
damage by plating in fresh medium without etoposide for 24 h.
2.3. In vitro phosphorylation
Recombinant wild-type or mutant hnRNPKs were pre-incu-
bated with human Aurora-A (Invitrogen, Carlsbad, CA) in kinase
buffer (50 mM Tris–Cl pH 7.5, 50 mM NaCl, 10 mM MgCl2, 1 mM
dithiothreitol) on ice for 10 min. Subsequently, a 0.1 mM ATP or
0.25 mCi/ml [c-32P]-ATP was added into solution and the reaction
was incubated at 30 C for 0.5–3 h. Reaction was then stopped and
prepared for further SDS–PAGE analysis.
2.4. Luciferase reporter assay
The Renilla luciferase with p21 30-UTR were transfected into
293T cells together with wild-type or mutant hnRNPK expression
plasmids by Turbofect™ reagent (Fermentas). b-galactosidase vec-
tor was co-transfected into cells as an internal control. Luciferase
activities were measured according to the recommended proce-
dures for Renilla luciferase assay system (Promega).
2.5. Immunoprecipitation, Phos-tag SDS–PAGE and western blot
Cell pellets were lysed by RIPA buffer (50 mM Tris pH 7.4,
150 mM NaCl, 0.5% Triton X-100, 0.25% sodium deoxycholate,
5 mM EDTA pH 8.0, 1 mM EGTA pH 8.0, 50 mM sodium ﬂuoride,
1 mM sodium vanadate and 10 mM sodium pyrophosphate with
general protease inhibitor (Sigma–Aldrich)). A 1 mg of total cell
lysate was incubated with primary antibody and protein G sephar-
ose beads (GE healthcare) at 4 C for 12–16 h. Beads were washed
six times with RIPA buffer, and the bounded proteins were ana-
lyzed by SDS–PAGE and transferred to PVDF membrane (Millipore,
Bedford, MA). For Phos-tag SDS–PAGE, 7% polyacrylamide gels con-
taining 25–50 lM Phos-tag acrylamide (Phos-tag Consortium,
Hiroshima, Japan) and 100 lM MnCl2 were performed according
to the manufacturer’s instructions [25]. Membrane was incubated
with blocking solution (5% non-fat milk in TBS/0.1% Tween-20) for
1 h and then incubated with primary antibody overnight at 4 C.
Secondary horseradish peroxidase-conjugated antibody was sub-
sequently incubated with membrane for 1 h at ambient tempera-
ture. Protein signals were detected by exposing the membrane to
X-ray ﬁlm after treating the membrane with ECL Western blotting
Detection Reagent (Millipore, Bedford, MA).
2.6. Identiﬁcation of phosphorylated peptides by mass spectrometry
The phosphorylated hnRNPK were reduced with 0.5 M dithio-
threitol, and alkylated with 0.5 M iodoacetamide. After removalof these reagents by triﬂuoroacetic acid precipitation, the resulting
pellet was washed with ice-cold acetone and dissolved in buffer
containing sequencing grade trypsin (Promega) in 25 mM
ammonium bicarbonate. Proteolysis was performed at 37 C for
12–16 h and phosphopeptides were enriched using Fe (III)-NTA
beads at ambient temperature for 15 min. After three washes with
100 mM acetic acid, the bound peptides were eluted off by 1%
phosphoric acid. For MALDI-TOF/TOF MS analysis (Ultraﬂex TOF/
TOF, Bruker Daltonics, Bremen, Germany), 0.5 ll samples were
mixed with 0.5 ll 2 mg/ml a-cyano-4-hydroxycinnamic acids in
50% acetonitrile and water with 0.1% triﬂuoroacetic acid on MALDI
target plate for MS analysis. Resulting data were processed using
BioTool, FlexAnalysis and Sequence Editor softwares supplied with
MS instrument.
3. Results
3.1. Aurora-A directly interacts with hnRNPK in vivo
To verify whether hnRNPK associates with Aurora-A in vivo, a
co-immunoprecipitation experiment was performed. Flag-Aurora-
A was overexpressed in HEK293 cells and immunoprecipitated
by anti-Flag antibody. The precipitates were examined by Western
blotting using anti-hnRNPK antibody and the presence of hnRNPK
could be observed (Fig. 2a). Alternatively, Aurora-A could also be
co-immunoprecipitated with hnRNPK (Fig. 2b), suggesting that
hnRNPK can directly interact with Aurora-A in vivo.
3.2. HnRNPK is a substrate of Aurora-A in vitro and in vivo
An in vitro kinase assay using recombinant hnRNPK and Aurora-
A in the presence of [c-32P]-ATP was carried out. Results showed
that hnRNPK can be phosphorylated by Aurora-A in vitro (Fig. 3a).
To further identify the Aurora-A-induced phosphorylation site of
hnRNPK, the phosphorylated hnRNPK was digested and analyzed
by mass spectrometry. All peptides whose mass matched to the
combination of any residue and a phosphate were subject to MS/
MS analysis for illustrating sequence. As shown in Fig. 3b, MS/MS
spectrum of a peptide at 1997.181 m/z, corresponding to the mass
of residue 378–396 (GSYGDLGGPIITTQVTIPK) plus 80 Da, demon-
strated the presence of a phosphorylated Ser-379. In addition, a
mutant hnRNPK carrying S379A substitution signiﬁcantly lost its
capacity to accept the phosphate when incubated with Aurora-A
and [c-32P]-ATP (Fig. 3c). Furthermore, a phosphate-sensitive
Phos-tag SDS–PAGE was used to monitor the phosphorylation
change of endogenous hnRNPK in HEK293 cells [25]. Upon transfec-
tion of Aurora-A, the nocodazole-synchronized cell exhibited the
higher expression and activity of Aurora-A as well as more phos-
phorylated isoform of hnRNPK (Fig. 3d). Moreover, use of Aurora-
A inhibitor (VX-680) could abolish the kinase activity [26] and
diminish the induced hnRNPK phosphorylation.
3.3. Ser-379 phosphorylation does not affect post-transcriptional
regulation and localization of hnRNPK
Previous study showed that hnRNPK represses translation of
p21 through binding to CU-rich sequence in 30-UTR of p21 mRNA
[27]. We thus transfected Luc-p21 30-UTR reporter plasmid into
HEK293T cells together with either wild-type or S379D mutant
hnRNPKs. Both wild-type and mutant hnRNPKs were able to
suppress Luciferase activity (Fig. 4a), implicating that Ser-379
phosphorylation does not affect the hnRNPK-mediated mRNA
a b
Fig. 2. Aurora-A interacts with hnRNPK in vivo. (a) Ectopically expressed Aurora-A (Flag-AIK) in HEK293 cell was immunoprecipitated with anti-Flag antibody and hnRNPK
was detected. (b) Immunoprecipitation with anti-hnRNPK antibody in HEK293 cells conﬁrmed the presence of Flag-AIK.
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Fig. 3. Aurora-A phosphorylates hnRNPK at Ser-379. (a) Wild-type hnRNPK was incubated with or without Aurora-A in the presence of [c-32P]-ATP. The reaction products
were separated on 10% SDS–PAGE and detected by autoradiography (b) MS/MS spectrum of peptide at 1996.843 m/z showed that the mass difference between y17 and y19
ions equals to the sum of a glycine and a phosphorylated serine, indicating the presence of a phosphorylated Ser-379. (c) Wild-type or S379A mutant hnRNPKs were
respectively incubated with Aurora-A in the presence of [c-32P]-ATP. The reaction products were separated on SDS–PAGE and detected by autoradiography (d) The Aurora-A-
expressing HEK293 cells were synchronized by 100 ng/ml nocodazole alone or together with 10 lM VX-680 and then separated by either SDS–PAGE or 7% Phos-tag SDS–
PAGE containing 50 lM Phos-tag acrylamide.
K.-W. Hsueh et al. / FEBS Letters 585 (2011) 2671–2675 2673translation. We further examined whether Ser-379 phosphoryla-
tion affects cellular localization of hnRNPK. As shown in Fig. 4b,
cellular distribution of S379D mutant hnRNP K is similar to that
of wild-type hnRNP K.
3.4. Ser-379 phosphomimic hnRNPK reduces its afﬁnity with p53
The involvement of hnRNPK in many processes arises from its
ability to interact with diverse partners [28]. Aurora-A has been
shown to phosphorylate p53 and abrogate its function. Moreover,
hnRNPK is a coactivator of p53 and can also be phosphorylated byAurora-A. We herein further examined whether Ser-379 phos-
phorylation interferes with the interaction of hnRNPK and p53.
The GST-p53 pull-down assay using various hnRNPKs was con-
ducted and the results showed that the wild-type hnRNPK
strongly bind to GST-p53 whereas the S379D mutant showed
much lower afﬁnity (Fig. 5a). Subsequently, ectopically expressed
p53 was immunoprecipitated from HEK293 cells expressing either
wild-type or S379D mutant hnRNPKs. Similarly, presence of S379D
hnRNPK is clearly lower than wild-type hnRNPK in p53 immuno-
precipitates (Fig. 5b). We next examined the effect of Aurora-A on
hnRNPK-p53 complex formation in cells undergone DNA damage,
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Fig. 4. Ser-379 phosphorylation of hnRNPK does not affect its post-transcriptional regulation and cellular localization. (a) The Luc-p21 30UTR and b-galactosidase were
transfected into HEK293 cells. Luciferase activity was measured and normalized to b-galactosidase after 48 h transfection. (b) Lysates of HEK293 cells transfected with wild-
type, S379D and S379A hnRNPKs were fractioned for cytosol and nucleus and level of hnRNPKs in each fraction were measured.
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Fig. 5. Ser-379 phosphorylation of hnRNPK disrupts its interaction with p53. (a) GST-p53 pull-down with wild-type and S379D hnRNPKs were performed and levels of
hnRNPK were detected. (b) Immunoprecipitation with antibody against p53 in HEK293 cells expressing wild-type or S379D hnRNPKs were respectively conducted to measure
the precipitated levels of hnRNPK. (c) Immunoprecipitation with antibody against hnRNPK in Aurora-A-expressing HEK293 cells treated with nocodazole or nocodazole/
etoposide were carried out to measure the hnRNPK-associated p53. Cells were recovered from damage by plating in fresh medium without etoposide for 24 h.
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synchronized in G2/M-phase by nocodazole, followed by treat-
ment with etoposide. The cells were then allowed to recover from
damage by plating in fresh medium without etoposide. The
hnRNPK-associated p53 was analyzed by immunoprecipitation
using an antibody against hnRNPK. As shown in Fig. 5c, the
amount of p53 in the hnRNPK immunoprecipitate decreased in
the mitosis-arrested cells which increased Aurora-A activity.
Exposure to etoposide increased hnRNPK-p53 complex formation,
consistent with the reduced Aurora-A activity during DNA dam-
age. Association of p53 and hnRNPK was barely detectable 24 h
after removal of etoposide as cells recovered from DNA damage.
These results demonstrated a tight correlation between Aurora-A
activity and hnRNPK-p53 complex formation in a physiological
context.4. Discussion
In this study, a Ser-379 phosphorylation of hnRNPK by Aurora-A
was identiﬁed. Interestingly, this phosphorylation site has been
revealed by global phosphoproteomic approaches but neither the
kinase nor the function was determined [30,31]. The 377-80 resi-
due of hnRNPK (RGSY) matches the consensus sequence (RXSL)
predicted for Aurora-A [32]. Our in vitro results demonstrated that
Aurora-A directly phosphorylates hnRNPK on Ser-379. Moreover,
the Phos-tag SDS–PAGE analysis showed an increased band from
phosphorylated hnRNPK upon Aurora-A activation in the
G2/M-synchronized cells. Together, we conclude that hnRNPK is
a novel substrate for Aurora-A.
Ser-379 is located between the nuclear shuttling domain (KNS)
(residues338–361) andKH3domain (residues391–439)of hnRNPK.
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affect hnRNPK localization or hnRNPK-mediated mRNA translation
[18,22]. In addition, hnRNPK was known to regulate mRNA transla-
tion of thymidine phosphorylase, p21, and androgen receptor
[21,27,33]. Our results showed that the localization and mRNA
translation ability of Ser379-phosphomimic hnRNPK is similar to
that of wild-type hnRNPK (Fig. 3).
We have shown by in vitro studies that phosphorylation on Ser-
379 of hnRNPK by Aurora-A disrupts its interaction with p53,
which was veriﬁed in vivo by following the course of transient eto-
poside treatment. We have shown that the interaction of hnRNPK
with p53 is inversely proportional to the activation status of
Aurora-A during the etoposide-induced DNA damage, which inhib-
its Aurora-A [29], and the subsequent recovery of its activity.
Although Aurora-A has been shown to suppress p53 activity and
stability via direct phosphorylation [11,12], our results have pro-
vided an additional mechanism that Aurora-A can regulates p53
activity indirectly by phosphorylating hnRNPK, an important
co-activator of p53 during DNA damage [14,23].
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